treatment
Low-Risk MDS
In this webinar, Dr. Andrew Matthews discusses Low Risk MDS, current treatments and what's on the treatment horizon. Dr. Matthews took many questions from the live audience.
Ashwin Kishtagari, MD
Kishtagari, Ashwin
Hematologist Oncologist
Vanderbilt University Medical Center
Online Profile:
David Hermel, MD
Hermel, David
Hematologist Oncologist
Scripps Clinic
David Hermel, MD, is a hematologist and medical oncologist who specializes in malignant hematology with an interest in the use of novel therapies, such as cellular immunotherapy and
Online Profile:
Rory Shallis Explains New Therapy for Patients with Low-Risk MDS, Imetelstat
Dr. Rory Shallis explains the treatment, Imetelstat, for patients with Low Risk MDS. Listen or read the transcript below.
NMDP and CIBMTR share new, promising stem cell transplantation trial data using mismatched, unrelated donors at the 2024 EHA Congress
MINNEAPOLIS, June 14, 2024 — NMDPSM, a global nonprofit leader in cell therapy, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) announced interim results from the ACCESS trial as an oral abstract during the European Hematology Association (EHA) Annual Meeting in Madrid, Spain.
Alain MIna, MD
Mina, Alain
Assistant Research Physician
National Cancer Institute - NCI
Online Profile:
FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia
Blood Transfusions and Iron Overload
In this webinar, Dr. Thomas Coates will discuss blood transfusions and the potential side effect, iron overload. You may submit questions in advance by emailing help@aamds.org.
Understanding Secondary AML: High-Risk MDS to AML
In this webinar, Dr. Nathan Punwani discusses the development of secondary AML from high risk MDS, treatment options and the quality of life impact for patients.